Nest.Bio Labs
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Nest.Bio Labs.
Key people at Nest.Bio Labs.
Key people at Nest.Bio Labs.
Nest.Bio Labs is a hybrid life sciences venture firm and shared lab operator that supports early-stage biotech startups through both physical infrastructure and active company creation. Its mission is to transform breakthrough life sciences and healthcare technologies into revolutionary therapeutics companies by combining incubation, venture building, and early-stage investing. Nest.Bio operates premier shared lab spaces in the Cambridge-Kendall Square biotech hub, offering flexible lab and office space to emerging life science ventures while simultaneously investing in and co-founding companies based on high-impact science.
The firm’s investment philosophy is operator-first and hands-on: it doesn’t just write checks but embeds itself in founding teams from day one, helping translate cutting-edge science into viable therapies. Nest.Bio focuses on biotechnology, health tech, AI in drug discovery, and data science, primarily at the pre-seed and seed stages. By integrating lab space, venture capital, and deep scientific and operational support, Nest.Bio has helped incubate more than 50 companies, supported over 1,000 local jobs, and contributed to a resident and alumni market cap exceeding $7 billion—making it a significant force in the early-stage biotech ecosystem.
---
Nest.Bio Labs was founded in 2018 with the opening of its first shared lab facility in Somerville, Massachusetts, strategically located in the heart of the Cambridge-Kendall Square biotech cluster near MIT and Harvard. While some sources cite a 2017 founding date for a related entity in Hangzhou, the U.S.-based Nest.Bio Labs emerged as a U.S.-headquartered venture and lab platform focused on bridging North American and Asian life sciences innovation.
The firm was built by a team of scientists, physicians, engineers, and investors with deep experience in biotech, machine learning, immunotherapy, and synthetic biology. From the outset, Nest.Bio differentiated itself by combining physical lab infrastructure with active company creation and early-stage investing. Rather than operating purely as a real estate provider or a traditional VC, it positioned itself as a “research, development, and venture firm” that could be “there from the beginning” of a company’s journey. Early traction came from attracting pioneering founders into its shared labs and then co-founding or backing ventures that leveraged frontier science in areas like cell therapy, precision medicine, and AI-driven drug discovery.
---
---
Nest.Bio Labs sits at the intersection of three powerful trends reshaping biotech and health innovation: the rise of decentralized, founder-friendly lab infrastructure; the increasing role of AI and data science in drug discovery; and the globalization of life sciences entrepreneurship. As the cost of experimentation falls and tools like CRISPR, single-cell sequencing, and generative AI become more accessible, a new wave of “garage biotech” startups is emerging—many of which need flexible, low-friction lab access and early-stage capital. Nest.Bio’s shared lab model directly addresses this need, lowering the barrier to entry for scientists turning academic insights into companies.
At the same time, the firm is riding the wave of AI-driven biotech, where machine learning is accelerating target discovery, biomarker identification, and therapeutic design. By combining wet-lab capabilities with a team fluent in both biology and data science, Nest.Bio is well-positioned to back ventures that sit at this convergence. Its cross-border focus also aligns with the growing interdependence of U.S. and Asian biotech ecosystems, where capital, talent, and regulatory pathways are increasingly fluid. In this context, Nest.Bio functions not just as a landlord or investor, but as a launchpad and amplifier for the next generation of biotech ventures.
---
Nest.Bio Labs is poised to deepen its role as a hybrid biotech launchpad—blending real estate, venture capital, and company creation into a single, high-leverage model. As the biotech ecosystem continues to fragment into more specialized, founder-centric platforms, firms like Nest.Bio that offer both space and strategic partnership will become increasingly valuable. The next phase will likely involve scaling its cross-border company creation engine, expanding its portfolio into new modalities (e.g., gene editing, microbiome, neurotech), and potentially replicating its lab-venture model in additional global hubs.
The firm’s success will depend on maintaining its scientific edge, staying close to academic and clinical pioneers, and continuing to attract top-tier founders who value hands-on support over passive capital. If it sustains its current trajectory, Nest.Bio could evolve into one of the defining biotech venture platforms of the 2020s—one that doesn’t just fund the future of medicine, but helps build it, molecule by molecule, company by company.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 1, 2018 | RootPath | $7.0M Seed | — | — |
| May 1, 2017 | Synlogic | $42.0M Series C | — | Atlas Venture, MPM Capital, Hakan Goker, Ed Mathers, New Enterprise Associates, RA Capital, Santé Ventures |
| Apr 1, 2009 | Aerovance | $38.0M Venture Round | — | — |
| Mar 1, 2007 | Aerovance | $60.0M Series C | — | — |
| Aug 1, 2004 | Aerovance | $32.0M Series B | — | — |
